CD274 and cancer: Anti-PD-L1 monotherapy and anti-PD-L1 + anti-VISTA combination therapy (p = 0.96) showed similar levels of cytotoxicity against cancer cells compared to the control group (p = 0.96 and p = 0.94, respectively).